Regulatory Mechanism of the Factor IX Gene^[*]

• 

Supported by National Institutes of Health grant HL38644 to K.K. and funds from the Hemophilia Foundation of Michigan, in addition to the University of Michigan Multipurpose Arthritis and Musculoskeletal Disease Center (NIH-5-P60-AR20557), the Geriatric Center (NIH-P30-AG08808), and the General Clinical Research Center (NIH-M01-RR00042).

• References

• 1 Saito H. Normal hemostatic mechanisms. In: Disorders of Hemostasis, 2nd edition. Ratnoff OD, Forbes CD. eds Philadelphia: Saunders; 1991. pp 18-47
• 2 Hedner U, Davie EW. Introduction to hemostasis and vitamin K-dependent coagulation factors. In: The Metabolic Basis of Inherited Diseases, 6th edition. Scriver CR, Beaudet AL, Sly WS, Valle D. eds New York: McGraw Hill; 1989. pp 2107-2134
• 3 Giannelli F, Green PM, High KA, Sommer S, Poon MC, Ludwig M. Haemophilia B: database of point mutations and short additions and deletions- fourth edition, 1993. Nucleic Acids Res 1993; 21: 3075-3087
• 4 Roberts HR. Molecular biology of hemophilia B. Thromb Haemost 1993; 70: 1-9
• 5 Kurachi K, Kurachi S, Furukawa M, Yao S-N. Biology of factor IX. Blood Coagul Fibrinolysis 1993; 4: 953-974
• 6 Ginsburg D, Sadler JE. von Willebrand disease: a database of point mutations, insertions, and deletions. Thromb Haemost 1993; 69: 177-84
• 7 White CG, Shoemaker BC. Factor VIII gene and hemophilia A. Blood 1989; 73: 1-12
• 8 Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
• 9 Sun X, Evatt B, Griffin JH. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood 1994; 83: 3120-3125
• 10 Otto JM, Grenett HE, Fuller GM. The coordinated regulation of fibrinogen gene transcription by hepatocyte-stimulating factor and dexamethasone. J Cell Biol 1987; 105: 1067-1072
• 11 Chodosh LA, Carthew RW, Morgan JG, Crabtree GR, Sharp PA. The adenovirus major late transcription factor activates the rat gamma-fibrinogen promoter. Science 1987; 238: 684-688
• 12 Courtois G, Morgan JG, Campbell LA, Fourel G, Crabtree GR. Interaction of a liver-specific nuclear factor with the fibrinogen and alpha 1-antitrypsin promoters. Science 1987; 238: 688-692
• 13 Bancroft JD, McDowell SA, Degen SJ. The human prothrombin gene: transcriptional regulation in HepG2 cells. Biochemistry 1992; 31: 12469-12476
• 14 Jamison CS, Degen SJ. Prenatal and postnatal expression of mRNA coding for rat prothrombin. Biochim Biophys Acta 1991; 1088: 208-216
• 15 Jamison CS, Burkey BF, Degen SJ. The effects of vitamin K1 and Warfarin on prothrombin expression in human hepatoblastoma (HepG2) cells. Thromb Haemost 1992; 68: 40-47
• 16 Miao CH, Leytus SP, Chung DW, Davie EW. Liver-specific expression of the gene coding for human factor X, a blood coagulation factor. J Biol Chem 1992; 267: 7395-7401
• 17 Mackman NSawdey, Keeton MR, Loskutoff DJ. Murine tissue factor gene expression in vivo. Tissue and cell specificity and regulation by lipopolysaccharide Am J Pathol 1993; 143: 76-84
• 18 Cui MZ, Parry GC, Edgington TS, Mackman N. Regulation of tissue factor gene expression in epithelial cells. Induction by serum and phorbol 12-myristate 13-acetate Arterioscler Thromb 1994; 14: 807-814
• 19 Bottles KD, Morrissey JH. Dexamethasone enhances agonist induction of tissue factor in monocytes but not in endothelial cells. Blood Coagul Fibrinolysis 1993; 4: 405-414
• 20 Kurachi K, Davie EW. Isolation and characterization of a cDNA coding for human factor IX. Proc Natl Acad Sci USA 1982; 79: 6461-6464
• 21 Choo KH, Gould KG, Rees DJ, Brownlee GG. Molecular cloning of the gene for human anti-haemophilic factor IX. Nature 1982; 299: 178-180
• 22 Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K. Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry 1985; 24: 3736-3750
• 23 Chance PF, Dyer KA, Kurachi K, Yoshitake S, Ropers H, Wieacker P, Garder SM. Regional localization of human factor IX gene by molecular hybridization. Human Genetics 1983; 65: 207-208
• 24 Kurachi S, Furukawa M, Salier J-P, Wu C-T, Wilson EJ, French FS, Kurachi K. Regulatory mechanism of human factor IX gene: protein binding at the Leyden-specific region. Biochemistry 1994; 33: 1580-1591
• 25 Anson DC, Choo KH, Rees DJ G, Giannelli F, Gould K, Huddleston JA, Brownlee GG. The gene structure of human anti-haemophilic factor IX. EMBOJ 1984; 3: 1053-1060
• 26 Salier J-P, Kurachi S, Kurachi K. Haemophilia B Leyden: natural rescues of a transient deficiency in transcription. Médecine Sciences 1994; 10: 186-194
• 27 Evans JP, Watzke HH, Ware JL, Stafford PW, High KA. Molecular cloning of a cDNA encoding canine factor IX. Blood 1989; 74: 207-212
• 28 Yao S-N, DeSilva AH, Kurachi S, Samuelson LC, Kurachi K. Characterization of a mouse factor IX cDNA and developmental regulation of the factor IX gene expression in liver. Thromb Haemost 1991; 65: 52-58
• 29 Drinkwater RD, Burgoyne LA, Skinner JD. Two human repetitive DNA elements: a new interspersed repeat found in the factor IX gene, and a satellite 11 tandem repeat sequence. Nucleic Acids Res 1986; 14: 9541
• 30 Sarkar G, Paynton C, Sommer SS. Segments containing alternating purine and pyrimidine dinucleotides: patterns of polymorphism in humans and prevalence throughout phylogeny. Nucleic Acids Res 1991; 19: 631-636
• 31 Sarkar G, Sommer SS. Access to a messenger RNA sequence or its protein product is not limited by tissue or species specificity. Science 1989; 244: 331-334
• 32 Hassan JH, Chelucci C, Peschle C, Sorrentino V. Transforming growth factor b (TGF-b) inhibits expression of fibrinogen and factor VII in a hepatoma cell line. Thromb Haemost 1992; 67: 478-483
• 33 Jallat S, Perraud F, Dalemans W, Balland A, Dieterle A, Faure T, Meulien P, Pavirani A. Characterization of recombinant human factor IX expressed in transgenic mice and in derived trans-immortalized hepatic cell lines. EMBOJ 1990; 9: 3295-3301
• 34 Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood 1992; 80: 1998-2005
• 35 Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Powers P. Development of the human coagulation system in the full-term infant. Blood 1987; 70: 165-72
• 36 Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Castle V, Powers P. Development of the human coagulation system in the healthy premature infant. Blood 1988; 72: 1651-1657
• 37 Hassan HJ, Leonardi A, Chelucci C, Mattia G, Macioce G, Guerriero R, Russo G, Mannucci PM, Peschle C. Blood coagulation factors in human embryonic-fetal development: preferential expression of the FVII/tissue factor pathway. Blood 1990; 76: 1158-1164
• 38 Kisker CT, Robillard JE, Clarke WR. Development of blood coagulation- a fetal lamb model. PediatrRes 1981; 15: 1045-1050
• 39 Hager K, Setzer J, Vogl T, Voit J, Platt D. Blood coagulation factors in the elderly. Arch Gerontol Geriatr 1989; 9: 277-282
• 40 Ibbotson SH, Tate GM, Davies JA. Thrombin activity by intrinsic activation of plasma in vitro accelerates with increasing age of the donor. Thromb Haemost 1992; 67: 377-380
• 41 Bauer KA, Weiss LM, Sparrow D, Vokonas PS, Rosenberg RD. Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative aging study J Clin Invest 1987; 80: 1527-1534
• 42 Hashimoto Y, Kobayashi A, Yamazaki N, Sugawara Y, Takada Y, Takada A. Relationship between age and plasma t-PA, PA-inhibitor and PA activity. Thromb Res 1987; 46: 625-633
• 43 Sweeney JD, Hoemig LA. Age-dependent effect on the level of factor IX. Am J Clin Pathol 1993; 99: 687-688
• 44 Hirosawa S, Fahner JB, Salier J-P, Wu C-T, Lovrien EW, Kurachi K. Structural and functional basis of the developmental regulation of human coagulation factor IX gene: Factor IX Leyden. Proc Natl Acad Sci USA 1990; 87: 4421-4215
• 45 Dombroski BA, Mathias SL, Nanthakumar E, Scott AF, Kazazian Jr HH. Isolation of an active human transposable element. Science 1991; 254: 1805-1808
• 46 Picketts DJ, Lillicrap DP, Mueller CR. Synergy between transcription factors DBP and C/EBP compensates for a haemophilia B Leyden factor IX mutation. Nat Genet 1993; 3: 175-179
• 47 Kurachi S, Kurachi K. Age and gender dependence of the factor IX gene expression in mice. Submitted for publication
• 48 de laSalle, Charmantier J-L, Baas MJ, Schwartz A, Wiesel M-L, Grunebaum L, Cazenave J-P. A deletion located in the 3’ non translated part of the factor IX gene responsible for mild haemophilia B. Thromb Haemost 1993; 70: 370-371
• 49 Vielhaber E, Jacobson DP, Ketterling RP, Liu J-Z, Sommer SS. A mutation in the 3’ untranslated region of the factor IX gene in four families with hemophilia B. Hum Mol Genet 1993; 2: 1309-1310
• 50 Briet E, Bertina RM, van TilburgN, Veitkamp JJ. Hemophilia B Leyden: a sex-linked hereditary disorder that improves after puberty. N Engl J Med 1982; 306: 788-790
• 51 Crossley M, Brownlee GG. Disruption of a C/EBP binding site in the factor IX promoter is associated with haemophilia B. Nature 1990; 345: 444-446
• 52 Crossley M, Ludwig M, Stowell KM, DeVox P, Olek K, Brownlee GG. Recovery from hemophilia B Leyden: an androgen response element in the factor IX promoter. Science 1992; 257: 377-379
• 53 Reijnen MJ, Sladek FM, Bertina RM, Reitsma PH. Disruption of a binding site for hepatocyte nuclear factor 4 results in hemophilia B Leyden. Proc Natl Acad Sci USA 1992; 89: 6300-6303
• 54 Vidaud D, Tartary M, Costa J-M, Bahnak BR, Gispert-Sanchez S, Fressinaud E, Gazengel C, Meyer D, Goossens M, Lavergne J-M, Vidaud M. Nucleotide substitutions at the 6 position in the promoter region of the factor IX gene result in different severity of hemophilia B Leyden: consequences for genetic counseling. Hum Genet 1993; 91: 241-244